Related Experiment Videos
Prevalence of cardiovascular damage in early renal disease
1University of British Columbia, Renal Insufficiency Clinic, Vancouver, Canada.
Insights
Early kidney disease patients often have left ventricular hypertrophy (LVH), linked to anemia and high blood pressure. Managing these risk factors may slow disease progression and improve cardiovascular outcomes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular disease (CVD) poses a significant risk in early renal disease.
- Left ventricular hypertrophy (LVH) is common in early stages of kidney decline and linked to modifiable risk factors like anemia and systolic blood pressure.
- Addressing these risk factors can potentially delay renal disease progression.
Purpose of the Study:
- To investigate the prevalence and predictors of LVH in early renal disease patients.
- To examine the association between hemoglobin (Hb) levels, blood pressure (BP), and LVH.
- To identify factors predicting left ventricular growth and cardiac symptom progression over 12 months.
Main Methods:
- Prospective, multicenter Canadian study involving 446 patients with early renal disease (pre-dialysis).
- Assessed baseline prevalence of LVH in relation to renal function and Hb levels.
- Monitored changes in Hb, systolic BP, and left ventricular mass index (LVMI) over 12 months.
Main Results:
- LVH prevalence increased with declining renal function and lower Hb levels.
- Even Hb levels within current guideline targets were associated with high LVH prevalence.
- Decreased Hb, increased systolic BP, and baseline LVMI predicted left ventricular growth over 12 months.
- Cardiac symptom progression was linked to a significant fall in BP and increase in LVMI.
Conclusions:
- Early identification and management of modifiable risk factors, including anemia and hypertension, are crucial in patients with early renal disease.
- Aggressive management of these factors may improve cardiovascular outcomes and slow disease progression.
- Further research is needed to optimize treatment strategies for reducing cardiovascular risk in this population.
Abstract:
There is a large burden of cardiovascular disease in early renal disease due to multiple risk factors. Although left ventricular hypertrophy (LVH) is prevalent early in the process of progressive renal decline, it is associated with a number of modifiable risk factors (e.g. anaemia and systolic blood pressure (BP)). More importantly, treatment of modifiable risk factors in renal disease can delay progression. It is important to define anaemia physiologically and to remember that it is also associated with a number of cardiovascular risk factors that may/may not be independent of each other. In a recent prospective, multicentre Canadian study of early renal disease patients prior to dialysis (n=446), the baseline prevalence of LVH increased both with decreasing renal function and decreasing haemoglobin (Hb) levels. Notably, Hb levels within current guideline target levels were still associated with a very high degree of LVH. Over a 12-month period, only a decrease in Hb and an increase in systolic BP, and baseline left ventricular mass index (LVMI) predicted left ventricular growth. Patients whose cardiac symptoms progressed over 12 months were those who experienced a significant fall in BP and a significant increase in LVMI during that time. In the future, steps are needed to ensure early identification of both renal disease and specific risk factors. Recognizing modifiable risk factors and addressing them early in the course of renal disease will facilitate the improvement of patient outcomes.